HomeCERS • NASDAQ
add
Cerus Corp
Previous close
$2.07
Day range
$1.81 - $2.09
Year range
$1.12 - $2.24
Market cap
359.20M USD
Avg Volume
1.37M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 52.70M | 14.52% |
Operating expense | 26.90M | -0.94% |
Net income | -19.00K | 99.35% |
Net profit margin | -0.04 | 99.37% |
Earnings per share | 0.00 | 100.00% |
EBITDA | 1.62M | 394.72% |
Effective tax rate | 130.77% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 78.51M | 3.90% |
Total assets | 215.18M | 13.53% |
Total liabilities | 152.98M | 13.10% |
Total equity | 62.20M | — |
Shares outstanding | 192.09M | — |
Price to book | 6.47 | — |
Return on assets | 1.44% | — |
Return on capital | 1.96% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -19.00K | 99.35% |
Cash from operations | 1.93M | -52.65% |
Cash from investing | -2.51M | -152.09% |
Cash from financing | 320.00K | 433.33% |
Net change in cash | -322.00K | -103.54% |
Free cash flow | -4.17M | -46.10% |
About
Cerus Corporation is an American multinational biotechnology company headquartered in Concord, California that develops and provides a treatment system to pathogen-reduce human blood products for the healthcare industry. Wikipedia
Founded
Sep 1991
Headquarters
Website
Employees
622
